Rabies immunoglobulin

Generic Medicine Info
Indications and Dosage
Postexposure prophylaxis of rabies
Adult: In conjunction with rabies vaccine in unvaccinated individuals: As human rabies immunoglobulin (HRIG): 20 IU/kg. As equine rabies immunoglobulin (ERIG): 40 IU/kg. Administer as a single dose on the 1st day of rabies vaccine (or within 7 days after) via infiltration into and around the cleansed wound. If infiltration of the whole volume is not possible, any remaining dose may be injected intramuscularly in the deltoid muscle of the upper arm or anterolateral thigh (distant from the site of rabies vaccine administration).
Child: Same as adult dose.
Special Precautions
Patients with IgA deficiency, bleeding disorders (e.g. thrombocytopenia) or those who are at risk of thrombosis (e.g. prolonged immobilisation, history of thrombosis, hyperviscosity syndrome). Children. Pregnancy and lactation.
Adverse Reactions
Significant: Haemolysis, bleeding, haematoma, fever; injection site reactions (e.g. swelling, pain, erythema, warmth).
Cardiac disorders: Tachycardia.
Gastrointestinal disorders: Nausea and vomiting.
General disorders and administration site conditions: Fatigue, malaise, influenza like illness.
Musculoskeletal and connective tissue disorders: Chills, arthralgia.
Nervous system disorders: Headache.
Skin and subcutaneous tissue disorders: Pruritus, rash, urticaria.
Potentially Fatal: Rarely, severe hypersensitivity reactions (e.g. anaphylactic shock).
IM/Parenteral: C
Monitoring Parameters
Perform skin testing prior to administration of ERIG.
Drug Interactions
May interfere with immune response to live attenuated virus vaccines. Immunosuppresive agents (e.g. alkylating agents, metabolites, corticosteroids, radiation) may increase risk of rabies infection due to decrease in antibody response to postexposure prophylaxis. Increased risk of bleeding with anticoagulants.
Lab Interference
May cause false-positive results in serological tests.
Description: Rabies immunoglobulin (RIG) is used for passive immunisation for individuals who are exposed to rabies virus and who have not been vaccinated against rabies. It provides immediate, temporary virus-neutralising antibodies until response to active immunisation with rabies vaccine is achieved. There are 2 kinds of rabies immunoglobulin based on their sources: human rabies immunoglobulin (HRIG) and highly purified equine rabies immunoglobulin (ERIG).
Absorption: Absorbed slowly after IM administration.
Excretion: Serum half-life: Approx 21 days (IM).
Store between 2-8°C. Do not freeze. Protect from light.
MIMS Class
Vaccines, Antisera & Immunologicals
ATC Classification
J06BB05 - rabies immunoglobulin ; Belongs to the class of specific immunoglobulins. Used in passive immunizations.
Anon. Rabies Immune Globulin (Human). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 08/11/2018.

Anon. Rabies Immune Globulin. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 08/11/2018.

Buckingham R (ed). Rabies Immunoglobulins. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/11/2018.

Hyperrab (Grifols USA, LLC.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 08/11/2018.

Joint Formulary Committee. Rabies Immunoglobulin. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/11/2018.

Rabies Vaccines and Immunoglobulins: WHO Position. World Health Organization. http://www.who.int/. Accessed 09/11/2018.

Disclaimer: This information is independently developed by MIMS based on Rabies immunoglobulin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in